Statistical Insights | Exploristics

Developments in Digital Data

Developments in Digital Data https://exploristics.com/wp-content/uploads/2022/02/Developments-in-Digital-Data-558-344.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2022/02/Developments-in-Digital-Data-558-344.jpg 3 February 2022 19 January 2024

Developments in Digital Data

By Exploristics Chief Data Scientific Officer – Kimberley Hacquoil

When I first started working in the pharmaceutical industry, most clinical trials used paper case report forms (CRF) to collect information from patients. I remember the very …

Why Simulation is Needed to Optimise Both Adaptive & Fixed Clinical Trial Designs

Simulation optimises adaptive and fixed trial designs

Simulation optimises adaptive and fixed trial designs https://exploristics.com/wp-content/uploads/2021/11/Why-Simulation-is-Needed-to-Optimise-Both-Adaptive-Fixed-Clinical-Trial-Designs-558-344.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2021/11/Why-Simulation-is-Needed-to-Optimise-Both-Adaptive-Fixed-Clinical-Trial-Designs-558-344.jpg 15 November 2021 14 November 2024

Why Simulation is Needed to Optimise Both Adaptive & Fixed Clinical Trial Designs

By Aiden Flynn, Exploristics CEO

Simulation is an invaluable tool for evaluating and mitigating the risks of clinical trials before conducting the studies in real time. Whilst …

Simulation can address recruitment challenges

Simulation can address recruitment challenges https://exploristics.com/wp-content/uploads/2021/10/Simulation-can-address-recruitment-challenges.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2021/10/Simulation-can-address-recruitment-challenges.jpg 24 October 2021 19 January 2024

By Aiden Flynn, Exploristics CEO

Ten common questions:

1. What is clinical trial simulation?

In general terms, simulation uses a mathematical model to describe a system and process (i.e., a clinical study). It can be used to test and …

Drug Repurposing and Real-World Data: Lessons from COVID-19

Drug Repurposing and Real-World Data: Lessons from COVID-19 https://exploristics.com/wp-content/uploads/2021/08/Drug-Repurposing-and-Real-World-Data-558-344.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2021/08/Drug-Repurposing-and-Real-World-Data-558-344.jpg 25 August 2021 19 January 2024

Statistical Insights: Drug Repurposing and RWD: Lessons from COVID: How the pandemic has heightened interest in unlocking the value of RWD.

by Aiden Flynn, CEO, Exploristics

The world has changed as a result of COVID-19. This is particularly true …

Designing clinical studies for success and not failure

Designing clinical studies for success and not failure https://exploristics.com/wp-content/uploads/2021/04/Designing-clinical-studies-for-success-and-not-failure-558-344.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2021/04/Designing-clinical-studies-for-success-and-not-failure-558-344.jpg 22 April 2021 19 January 2024

Statistical Insights: Designing clinical studies for success and not failure.

by Aiden Flynn, CEO, Exploristics

One of the most common complaints I have heard from biostatisticians is that they don’t get involved early enough in the clinical trial …

Going Synthetic with Real-World Data

Going Synthetic with Real-World Data https://exploristics.com/wp-content/uploads/2021/03/Going-Synthetic-with-Real-World-Data-558-344.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2021/03/Going-Synthetic-with-Real-World-Data-558-344.jpg 10 March 2021 19 January 2024

Aiden Flynn, CEO

Real-world data has the potential to have a positive impact on the treatment of serious conditions, providing much-needed insights into the health and treatment of patients in an everyday setting. However, the collection of this data can …

The liberation of real-world data

The liberation of real-world data https://exploristics.com/wp-content/uploads/2021/03/The-liberation-of-real-world-data-558-344.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2021/03/The-liberation-of-real-world-data-558-344.jpg 10 March 2021 19 January 2024

Aiden Flynn, CEO

The costs and complexities associated with drug development are fuelling the drive for more efficient healthcare delivery. Using real-world data resources leads to better informed projects, improved patient outcomes and a more effective evaluation of success. This …

Belfast is where Exploristics’ heart is

Belfast is where Exploristics’ heart is https://exploristics.com/wp-content/uploads/2021/02/Belfast_At_Night_558-344.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2021/02/Belfast_At_Night_558-344.jpg 24 February 2021 19 January 2024

Aiden Flynn, CEO 24 February 2021

As a business founder I am fascinated by the back stories of others who have decided to take a leap of faith and start their own businesses. It takes incredible courage, tenacity, resilience and …

Why Getting Smaller Doesn’t Mean Thinking Smaller

Why Getting Smaller Doesn’t Mean Thinking Smaller https://exploristics.com/wp-content/uploads/2021/01/getting-smaller558-344.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2021/01/getting-smaller558-344.jpg 5 January 2021 19 January 2024

Aiden Flynn, CEO 05 January 2021

In the wake of a tumultuous 2020, I have taken the opportunity to reflect on the progress Exploristics has made as a company and reappraise my reasons for setting it up. This seems fitting …

Clinical trials after COVID-19

Clinical trials after COVID-19 https://exploristics.com/wp-content/uploads/2020/08/Clinical-trials-after-COVID-19-558-344.jpg 558 344 Exploristics Exploristics https://exploristics.com/wp-content/uploads/2020/08/Clinical-trials-after-COVID-19-558-344.jpg 11 August 2020 29 January 2025

Aiden Flynn, CEO 11 August 2020

The challenges faced by the Pharmaceutical Industry have been well documented: the high costs of clinical trials; the high rates of attrition; higher regulatory scrutiny; limited scope to pay high costs of new medicines; …